title: Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.
abstract: Bcr-Abl constitutes a deregulated tyrosine kinase involved in the pathogenesis of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL). Although activation of the transcription factor NF-kappaB/Rel has been demonstrated, mechanisms of NF-kappaB/Rel activation by Bcr-Abl remain obscure. In this paper we demonstrate activation of NF-kappaB/Rel by Bcr-Abl and for the first time by v-Abl. Furthermore, we investigated mechanisms of NF-kappaB/Rel induction by Bcr-Abl and v-Abl. Both Bcr-Abl and v-Abl induced NF-kappaB/Rel DNA binding in Ba/F3 cells. DNA binding was a result of nuclear translocation of p65/RelA, whereas p65/RelA expression was unaffected. Nuclear translocation of p65/RelA is at least partially due to increased IkappaBalpha degradation, which is independent of IkappaB kinase (IKK) activity. IKK activity is not deregulated by Bcr-Abl and v-Abl. NF-kappaB/Rel transactivation was dependent on abl kinase activity but independent of Grb2 and Grb10 binding tobcr sequences. In addition, NF-kappaB/Rel activation was dependent on Ras activity. Primary CML blasts showed constitutive p65/RelA NF-kappaB/Rel DNA binding activity. Thus NF-kappaB/Rel represents a potential target for molecular therapies in CML.
authors.affiliation: Abteilung Innere Medizin III, Universität Ulm, Ulm, Germany.
authors.forename: Dieter
authors.initials: D
authors.lastname: Kirchner
authors.forename: Justus
authors.initials: J
authors.lastname: Duyster
authors.forename: Oliver
authors.initials: O
authors.lastname: Ottmann
authors.forename: Roland M
authors.initials: RM
authors.lastname: Schmid
authors.forename: Lothar
authors.initials: L
authors.lastname: Bergmann
authors.forename: Gerd
authors.initials: G
authors.lastname: Munzert
mesh_terms: D021581:Active Transport, Cell Nucleus; D000818:Animals; D002460:Cell Line; D004247:DNA / Q000378:metabolism; D016044:Fusion Proteins, bcr-abl / Q000502:physiology*; D006801:Humans; D051550:I-kappa B Kinase; D020672:I-kappa B Proteins / Q000378:metabolism; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology; D051379:Mice; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism*; D016374:Oncogene Proteins v-abl / Q000502:physiology; D020572:Oncogene Proteins v-rel / Q000378:metabolism*; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D015533:Transcriptional Activation; D018631:ras Proteins
chemical_list: D020672:I-kappa B Proteins; D016328:NF-kappa B; C000606204:NFKBIA protein, human; C000606205:Nfkbia protein, mouse; D016374:Oncogene Proteins v-abl; D020572:Oncogene Proteins v-rel; D000072000:NF-KappaB Inhibitor alpha; D004247:DNA; D016044:Fusion Proteins, bcr-abl; D017346:Protein Serine-Threonine Kinases; C496559:CHUK protein, human; C496564:Chuk protein, mouse; D051550:I-kappa B Kinase; C496560:IKBKB protein, human; C496565:IKBKE protein, human; C496562:Ikbkb protein, mouse; C496566:Ikbke protein, mouse; D018631:ras Proteins